Pharmacological restoration of FoxO3 activity, in part, successfully reverted the IPF phenotype [4,5], thereby reinforcing FoxO as a potent therapeutic target for pulmonary catastrophes. The gene discussed is FOXO3; the disease is idiopathic pulmonary fibrosis.